Meningococcal disease - Some issues in treatment

Journal of Infection

Volumn 42, Issue 2, 2001, Pages 87-99

  Wall, R A ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBODY CONJUGATE; CHLORAMPHENICOL; DEXAMETHASONE; HYDROCORTISONE; MENINGOCOCCUS VACCINE; PENICILLIN G; STEROID; STREPTOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; DRUG CHOICE; ENVIRONMENTAL FACTOR; GENETICS; HOST RESISTANCE; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PENICILLIN RESISTANCE; VIRUS INFECTION;

EID: 0034930094     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2001.0813     Document Type: Article

References (186)

1. Memoire sur le maladie qui a régné à Geneve au printemps de 1805
2. Medical and agricultural register 1806 vol 1: no. 5
3. Early diagnosis and intravenous serum treatment of epidemic cerebrospinal meningitis
4. Serum treatment of epidemic cerebrospinal meningitis
5. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58
6. Complete DNA sequence of a serogroup. A strain of Neisseria meningitidis Z2491
7. Pathogenesis of meningococcal infections
8. Meningococcal disease falls in vaccine recipients
9. Host responses to meningococcal infections
10. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers
11. Population genetics and molecular epidemiology of Neisseria meningitidis
12. Pathogenic neisseria: Complexity of pathogen-host interplay
13. Virulence linked to polysaccharide production in serogroup B Neisseria meningitidis
14. Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in the Gambia, West Africa
15. The lipo-oligosaccharide immunotype as a virulence determinant in Neisseria meningitidis
16. Endotoxin liberation and invasivity of Neisseria meningitidis
17. Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases
18. Endotoxin liberation by strains of N. meningitidis isolated from patients and healthy carriers
19. Endotoxin liberation from Neisseria meningitidis correlates to their ability to induce procoagulant and fibrinolytic factors in human monocytes
20. Endotoxin release and cytokine production in acute and chronic meningococcaemia
21. Genetic basis for biosynthesis, structure. and function of meningococcal lipooligsaccharide (Endotoxin)
22. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells
23. Invasive Isolates of Neisseria meningitidis possess enhanced immunoglobulin A1 protease activity compared to colonising strains
24. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease
25. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis
26. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy
27. Pili and outer membrane appendages on Neisseria meningitidis in the cerebrospinal fluid of an infant
28. Epitopes of serogroup B Neisseria meningitidis analysed in vitro and directly from cerebrospinal fluid
29. Ability of gonococcal and meningococcal lipooligosaccharides to clot Limulus amebocyte lysate
30. Complement activation and endotoxin levels in systemic meningococcal disease
31. Endotoxin and meningococcaemia. Intravascular inflammation induced by native endotoxin in man
32. Complement activation in relation to capillary leakage in children with septic shock and purpura
33. Neisseria meningitidis bacteraemia in children: Quantitation of bacteraemia and spontaneous clinical recovery without antibiotic therapy
34. Magnitude of bacteraemia and complement activation during Neisseria meningitidis infection: Study of two co-primary cases with different clinical presentations
35. Meningococcic Infection in an army camp
36. The treatment of meningococcic infections with sulfadiazine and sulfamerazine
37. Meningococcal infections at an army training center
38. The treatment of meningococcal infections with especial reference to the Waterhouse-Friderichsen syndrome
39. Antigen-negative meningitis due to group A Neisseria meningitidis
40. Human immunity to the meningococcus. I. The role of humoral antibodies
41. Serum opsonins to serogroup B meningococci in meningococcal disease
42. Compartmentalisation of lipopolysaccharide production correlates with clinical presentation of meningococcal disease
43. Postsplenectomy sepsis. Perspect
44. Fulminant meningococcaemia after splenectomy
45. Mannose-binding lectin and meningococcal disease
46. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency
47. Familial properdin deficiency and fatal meningococcaemia
48. FCy Receptor IIa (CD32) polymorphism in fulminant septic shock in children
49. Association of human Fc gamma RIIa polymorphism with susceptibility to and severity of meningococcal disease
50. The relationship between plasminogen activator inhibitor 1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock
51. 4G/5G promoter polymorphisms in the plaminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
52. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
53. Effect of the Factor V Leiden mutatation on the severity of meningococcal disease
54. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
55. Release of tumor necrosis factor: An innate host characteristic that may contribute to the outcome of meningococcal disease
56. Variation in the tumor necrosis factor-a gene promoter region may be associated with death from meningococcal disease
57. Genetic influence on cytokine production and fatal meningococcal disease
58. Bacterial endotoxin: Chemical constitution, biological recognition, host response and immunological detoxification
59. Golenbock Lipopolysaccharide recognition. CD14, and Lipopolysaccharide receptors
60. The toll of innate immunity on microbial pathogens
61. Pstl-polymorphism in the human bactericidal increasing protein (BPI) gene
62. Bacterial meningitis
63. Sequelae one year after meningococcal disease
64. Treatment of bacterial meningitis
65. Consensus statement on diagnosis, investigation, treatment and prevention of acute bacterial meningitis in immunocompetent adults
66. The critically ill child: Management of acute bacterial meningitis
67. Waterhouse-Friderichsen syndrome caused by Haemophilus influenzae type b
68. Apparent meningococcaemia: Clinical features of disease due to Haemophilus influenzae and Neisseria meningitidis
69. Non-meningococcal purpuric sepsis
70. Adult Haemophilus influenzae meningitis associated with disseminated intravascular coagulation
71. Waterhouse-Friderichsen syndrome caused by Haemophilus influenzae in an adult
72. Fatal haemophilus influenzae type f infection
73. The syndrome of asplenia, pneumococcal sepsis, and disseminated intravascular coagulation
74. Symmetrical peripheral gangrene (Purpura fulminans) complicating pneumococcal sepsis
75. Rapidly fatal pneumococcal sepsis in a healthy adult
76. Pneumococcal meningoencephalitis associated with purpura fulminans in a non-splenectomised subject
77. Waterhouse-Friderichsen syndrome due to Streptococcus pneumoniae in an otherwise healthy adult
78. Purpura fulminans associated with Streptococcus pneumoniae infection in a child
79. Haemorrhage and shock associated with invasive pneumococcal infection in healthy infants and children - New Mexico. 1993-94
80. Clinical manifestations caused by group A streptococci
81. Staphylococcal septicaemia and disseminated intravascular coagulation
82. Staphylococcus aureus endocarditis presenting as meningitis and mimicking meningococcal sepsis
83. Treatment of acute renal failure, symmetrical peripheral gangrene, and septicaemia with plasma exchange and epoprostenol
84. General principles of therapy of pyogenic meningitis
85. Delayed cerebrospinal fluid sterilisation and adverse outcome of bacterial meningitis in infants and children
86. Pharmacodynamics of antibiotics in the therapy of meningitis: Infection model observations
87. Antibiotic pharmacodynamics in cerebrospinal fluid
88. A pharmacologic evaluation of penicillin in children with purulent meningitis
89. The penetration of broad-spectrum antibiotics into the cerebrospinal fluid
90. Ampicillin levels in the cerebrospinal fluid during treatment of bacterial meningitis
91. Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis
92. Treatment of bacterial meningitis with once daily ceftriaxone therapy
93. Efficacy of ceftriaxone in treatment of serious childhood infections
94. Comparison of Ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis
95. Comparative activity in vitro of 16 antimicrobial agents against penicillin-susceptible meningococci and meningococci with diminished susceptibility to penicillin
96. E Test as a susceptibility test and epidemiological tool for evaluation of Neisseria meningitidis isolates
97. Antimicrobial susceptibility of penicillin-sensitive and penicillin-resistant meningococci
98. Discriminative criteria for Neisseria meningitidis isolates that are moderately susceptible to penicillin and ampicillin
99. In vitro susceptibility of meningococci to eleven antibiotics and sulfadiazine
100. Ampicillin in the treatment of acute meningitis
101. Changing susceptibility of meningococci to antimicrobial agents
102. Isolation of Neisseria meningitidis strains with increase of penicillin minimal inhibitory concentrations
103. Neisseria meningitidis strains with decreased susceptibility to penicillin
104. Meningococci moderately resistant to penicillin
105. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: A 5-year history (1985-1989)
106. Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species
107. Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece
108. Isolation of moderately penicillin-susceptible strains of Neisseria meningitidis in Argentina
109. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina
110. Neisseria meningitidis with decreased susceptibility to penicillin in Saskatchewan, Canada
111. Epidemiological survey of Neisseria meningitidis to penicillin G in France
112. Penicillin-insensitive meningococci in the UK
113. Meningococcal disease in England and Wales: 1995
114. Neisseria meningitidis with reduced sensitivity to penicillin: Observations in 10 children
115. Meningococci with increased resistance to penicillin
116. Clinical data in children with meningococcal meningitis in a Spanish hospital
117. Penicillin-resistant Neisseria meningitidis
118. Penicillin and meningococci
119. A study of bacterial meningitis in Kumasi, Ghana
120. Changing patterns of antibiotic sensitivity and resistance during an outbreak of meningococcal infection in Jos, Nigeria
121. Penicillin-resistant Neisseria meningitidis in Southern Africa
122. Fracaso del tratamiento con penicilina en un caso de meningitis por Neisseria meningitidis
123. Meningococcal meningitis during penicillin therapy for meningoccaemia
124. Inducement of Neisseria meningitidis resistance to ampicillin and penicillin in a patient with meningococcaemia treated with high doses of ampicillin
125. Spread of penicillinase-producing and transfer plasmids from the gonococcus to Neisseria meningitidis
126. Penicillin-resistant beta-lactamase producing Neisseria meningitidis in Spain
127. Isolation of a strain of beta-lactamase-producing Neisseria meningitidis in Spain
128. Aislamiento de dos cepas de Neisseria meningitidis serogrupo C productoras de betalactamasa
129. Neurotoxicity of beta-lactam antibiotics: Predisposing factors and pathogenesis
130. Neurotoxicity and "Massive" intravenous therapy with penicillin, a study of possible predisposing factors
131. Group-specific polysaccharide antigen and humoral antibody response in disease due to Neisseria meningitidis
132. Immunological investigations of meningococcal disease. II. Some characteristics of Group C antigen of Neisseria meningitidis in the sera of patients with fulminant meningococcaemia
133. Meningococcal antigen in diagnosis and treatment of Group A meningococcal infections
134. Structure-function relationships of bacterial endotoxins
135. Cerebrospinal fluid endotoxin levels in children with H. influenzae meningitis before and after administration of intravenous ceftriaxone
136. Antimicrobial and anti-inflammatory treatment of bacterial meningitis
137. Dexamethasone as adjunctive therapy in bacterial meningitis: A meta-analysis of randomised clinical trials since 1998
138. Bacterial meningitis
139. The Endotoxin-liberating effect of antibiotics on meningococci in vitro
140. Effect of penicillin on the morphology of a Neisseria strain liberating free endotoxin
141. Effect of penicillin and chloramphenicol on the growth and endotoxin release by N. meningitidis
142. No increase in endotoxin release during antibiotic killing of meningococci
143. Effect of benzylpenicillin in mice infected with endotoxin-liberating or non-liberating variant strains of Neisseria meningitidis
144. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release
145. Cytokines in meningococcal disease
146. The biologic activities of peptidoglycan in experimental Haemophilus influenzae meningitis
147. The induction of meningeal inflammation and blood-brain barrier permeability by haemophilus influenzae type b peptidoglycan
148. Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa
149. Arthropathic properties of gonococcal peptidoglycan fragments: Implications for the pathogenesis of disseminated gonococcal disease
150. Prediction of morbidity in Hemophilus influenzae meningitis
151. Prospective evaluation of treatment of Hemophilus influenzae meningitis
152. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis
153. Prognostic value of the precipitin test in meningococcus meningitis
154. Concentrations bacteriennes dans le liquide cephalorachidien au cours des meningites de l'enfant
155. Bacterial count in the cerebrospinal fluid of patients with Neisseria meningitidis: Meningitis comparison with other bacterial meningitis
156. Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitidis and its diagnostic significance
157. Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis
158. Outcomes of bacterial meningitis in children: A meta-analysis
159. Meningococcosis a protean disease
160. Hearing loss during bacterial meningitis
161. Steroid controversy in sepsis and septic shock: A meta-analysis
162. Steroids in the treatment of clinical septic shock
163. Corticosteroids for the treatment of septic shock
164. Reversible adrenocorticol insufficiency in fulminant meningococcaemia
165. Adrenal failure in fulminant meningococcal septicaemia: A clinical reality
166. Study of adrenal function in children with meningitis
167. Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease. Evidence of adrenal insufficiency?
168. The adrenal response to exogenous adrenocorticotrophin in patients with infections due to Neisseria meningitidis
169. Adrenal insufficiency in septic shock
170. Update on meningococcal disease with emphasis on pathogenesis and clinical management
171. Meningitis - A diagnostic dilemma
172. Meningococcal bacteraemia in febrile contacts of patients with meningococcal disease
173. Acute bacterial meningitis in childhood: Aspects of prehospital care in 687 cases
174. Bacterial meningitis: Causes of concern
175. Meningococcal disease in a large urban population (Barcelona, 1987-1992)
176. Duration of symptoms and outcome in bacterial meningitis: An analysis of causation and the implications of a delay in diagnosis
177. Meningococcal infections: Reducing the case fatality rate by giving penicillin before admission to hospital
178. Early treatment with parenteral penicillin in meningococcal disease
179. Early parenteral penicillin in meningococcal disease
180. Early treatment of meningococcal disease
181. Early management of meningococcal disease
182. Early management of meningococcal disease
183. Early treatment of meningococcal disease
184. Outcome of pre-hospital treatment of meningococcal disease